This case report highlights a treatment showing durable remission in frail patients with DLBCL, suggesting a viable option for intensive therapies.
Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose modification.
No takes yet. Share an insight, caveat, or question.
Dada et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: